AWIQLI

This brand name is authorized in Lithuania.

Active ingredients

The drug AWIQLI contains one active pharmaceutical ingredient (API):

1	Insulin icodec UNII P7YU3ED05N - INSULIN ICODEC
	The primary action of insulin, including insulin icodec, is to regulate glucose metabolism. A slow and steady glucose-lowering effect of insulin icodec is driven by albumin binding as well as reduced insulin receptor binding and clearance. The extended half-life of insulin icodec reflects a depot of insulin icodec in the circulation and in the interstitial compartment, from which insulin icodec is slowly and continuously released and binds specifically to the insulin receptor.
	Read more about Insulin icodec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AWIQLI Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10AE07		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AE Insulins and analogues for injection, long-acting
Discover more medicines within A10AE07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1099876, 1099877, 1099878, 1099879, 1099880, 1099881, 1099882, 1099883, 1099884, 1099885, 1099886, 1099887, 1099888, 1099889